Results 31 to 40 of about 78,184 (307)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia [PDF]

, 2015
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins ...
A Puissant, AJ Mohamed, BD Smith, BJ Druker, C Chung, C Dos Santos, C Thiede, C Venkataraman, CC Smith, CK Hahn, F Heidel, F Honda, G Juliusson, H Kiyoi, HS Ma, J Adolfsson, JA Dubovsky, JA Dubovsky, JA Woyach, JA Woyach, JB Petro, K Fiedler, KU Birkenkamp, L Zaitseva, M Levis, M Nakao, ML Wang, N Feldhahn, NJ Horwood, PP Zarrinkar, Q Xu, RF Schlenk, RM Stone, S Knapper, S Meshinchi, SA Ezell, SA Rushworth, SA Rushworth, SA Rushworth, SA Rushworth, T Kindler, T Matsunaga, T Oellerich, T-l Gu, V Vijayan, W Gao, Y Alvarado, Y Baba, Y Yamamoto, Y-T Tai   +49 more
core   +2 more sources

Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector

Molecular Therapy: Methods & Clinical Development, 2021
X-linked agammaglobulinemia (XLA) is an immune disorder caused by mutations in Bruton’s tyrosine kinase (BTK). BTK is expressed in B and myeloid cells, and its deficiency results in a lack of mature B cells and protective antibodies.
Brenda J. Seymour, Swati Singh, Hannah M. Certo, Karen Sommer, Blythe D. Sather, Socheath Khim, Courtnee Clough, Malika Hale, Joseph Pangallo, Byoung Y. Ryu, Iram F. Khan, Jennifer E. Adair, David J. Rawlings   +12 more
doaj   +1 more source

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]

, 2014
Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Bowles, Kristian M, Lawes, Matthew J, MacEwan, David J, Murray, Megan Y, Rushworth, Stuart A, Shafat, Manar S., Zaitseva, Lyubov   +6 more
core   +2 more sources

Amplifying Btk's Signal [PDF]

Immunity, 2003
The Tec kinase Btk is an important regulator of antigen receptor activation of phospholipase C-gamma (PLC-gamma). Data from Carpenter and colleagues (Saito et al., this issue of Immunity) now suggest that Btk also activates phosphatidylinositol-4-phosphate 5-kinase (PIP5K), thereby stimulating a positive feedback loop that generates PI(4,5)P2, the ...
openaire   +2 more sources

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

Blood Advances, 2022
The covalent Bruton’s tyrosine kinase inhibitors (BTKis) are highly effective for the treatment of chronic lymphocytic leukemia (CLL). The dominant resistance mechanism observed with the BTKi ibrutinib is the development of BTK Cys481 codon mutations ...
P. Blombery, E. Thompson, T. Lew, I. Tiong, R. Bennett, C. Cheah, K. Lewis, S. Handunnetti, C. P. S. Tang, A. Roberts, J. Seymour, C. Tam   +11 more
semanticscholar   +1 more source

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System

Journal of Inflammation Research, 2022
Tingyu Cao,1 Zengguang Wang,2 Xiaodong Zhu1 1Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China; 2Department of Neurosurgery, Tianjin Neurological Institute, Tianjin ...
Cao T, Wang Z, Zhu X
doaj  

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. [PDF]

, 2017
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown.
Brennan, Cameron W., Campos, Carl, Clark, Owen, Codega, Paolo, DeAngelis, Lisa M., Dogan, Ahmet, Gavrilovic, Igor T., Glass, Jon, Graeber, Thomas G., Grommes, Christian, Gutin, Philip H., Hamlin, Paul, Hatzoglou, Vaios, Hsieh, Wan-Ying, Huse, Jason T., Kaley, Thomas J., Lallana, Enrico C., Mellinghoff, Ingo K., Moskowitz, Craig H., Nichol, Donna, Nolan, Craig P., Noy, Ariela, Omuro, Antonio, Palaskas, Nicolaos, Palomba, M. Lia, Panageas, Katherine S., Pastore, Alessandro, Peak, Scott, Pentsova, Elena, Reiner, Anne S., Rohle, Dan, Rosenblum, Marc, Sauter, Craig S., Schartz, Derrek, Schultz, Nikolaus, Tabar, Viviane S., Tang, Sarah S., Thomas, Alissa A., Tsyvkin, Elina, Viale, Agnes, Wolfe, Julia, Won, Minhee   +41 more
core   +2 more sources

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma

Journal of Clinical Investigation, 2023
Bruton’s tyrosine kinase (BTK) is a proven target in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma. However, resistance to BTK inhibitors is a major clinical challenge. We here report that MALT1 is one of the top overexpressed
V. Jiang, Yang Liu, Junwei Lian, Shengjian Huang, Alexa A Jordan, Qingsong Cai, R. Lin, F. Yan, J. McIntosh, Yijing Li, Y. Che, Zhihong Chen, J. Vargas, M. Badillo, John Bigcal, H. Lee, W. Wang, Yixin Yao, L. Nie, C. Flowers, Michael Wang   +20 more
semanticscholar   +1 more source

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

Journal of Experimental Pharmacology, 2021
Francesco Paolo Tambaro,1 Danilo De Novellis,1,2 William G Wierda3 1Unità Operativa di Trapianto di Midollo Osseo e Servizio Trasfusionale, Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, Napoli, Italy; 2Department of Precision Medicine ...
Tambaro FP, De Novellis D, Wierda WG
doaj  

Phylloplane Sterilization With Bleach Does Not Reduce Btk Toxicity for \u3ci\u3ePapilio Glaucus\u3c/i\u3e Larvae (Lepidoptera: Papilionidae) [PDF]

, 2018
Neonate tiger swallowtail larvae (Papilio glaucus) were used to bioassay the effects of Btk (Bacillus thuringiensis var. kurstaki) at 4 doses (0.268, 0.034, 0.008, and 0.004 BIU per cm leaf surface) with an untreated control.
Haas, Laura, Scriber, J. Mark
core   +2 more sources